百济神州(6160.HK)逆势涨近10% 融资20.8亿美元刷新全球生物科技领域股权融资纪录
格隆汇7月14日丨百济神州(6160.HK)逆势大涨,盘中一度涨超13%至138港元,再创历史新高,现涨9.87%报133.6港元,暂成交6193万港元,最新总市值1356亿港元。公司昨日宣布,向特定现有投资者发行145,838,979股,约占发行后股份总数的12.5%,购买价为14.2308美元/股(185美元/ADS),发行总收入约为20.8亿美元,扣除发行费用后的净收入为20.7亿美元,这是迄今为止全球生物科技领域内最大规模的股权融资。其中,高瓴认购不低于10亿美元的份额。此前高瓴参与和支持了百济神州共计7轮的融资。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.